Computerized battery

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir

Authors: Kevin Robertson, Paul Maruff, Lisa L. Ross, David Wohl, Catherine B Small, Howard Edelstein & Mark S. Shaefer

Journal: Journal of Neurovirology

Year Published: 2019

Human immunodeficiency virus (HIV)-associated neurocognitive disorders can persist in many patients despite achieving viral suppression while on antiretroviral therapy (ART). Neurocognitive function over 48 weeks was evaluated using a Cogstate test battery assessing psychomotor function, attention, […]

Back to Publications